Compare SWAG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWAG | CVM |
|---|---|---|
| Founded | 1994 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 30.1M |
| IPO Year | 2021 | 1996 |
| Metric | SWAG | CVM |
|---|---|---|
| Price | $1.37 | $1.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 18.6K | ★ 253.1K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.82 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $116,191,000.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.17 | ★ N/A |
| Revenue Growth | 40.58 | ★ 65.45 |
| 52 Week Low | $1.32 | $0.89 |
| 52 Week High | $3.50 | $10.24 |
| Indicator | SWAG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 35.50 | 49.64 |
| Support Level | $1.32 | $1.01 |
| Resistance Level | $1.84 | $4.84 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.92 | 15.88 |
Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.